Renaissance Technologies
BLRX

Renaissance Technologies’s BioLineRX BLRX Stock Holding History

Renaissance Technologies’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.1K Buy
+15,412
New +$44.7K ﹤0.01% 3050
2023
Q3 		– Sell
-2,468
Closed -$157K – 3681
2023
Q2 		$157K Sell
2,468
-184
-7% -$10.2K ﹤0.01% 3350
2023
Q1 		$94K Sell
2,652
-3,796
-59% -$99.8K ﹤0.01% 3508
2022
Q4 		$152K Buy
6,448
+4,742
+278% +$141K ﹤0.01% 3502
2022
Q3 		$63K Buy
1,706
+562
+49% +$32.1K ﹤0.01% 3702
2022
Q2 		$59K Sell
1,144
-540
-32% -$30K ﹤0.01% 3965
2022
Q1 		$115K Buy
1,684
+1,331
+377% +$92.7K ﹤0.01% 3768
2021
Q4 		$29K Sell
353
-72
-17% -$7.51K ﹤0.01% 3823
2021
Q3 		$47K Sell
425
-1,520
-78% -$180K ﹤0.01% 3376
2021
Q2 		$219K Sell
1,945
-10,683
-85% -$1.26M ﹤0.01% 3228
2021
Q1 		$1.41M Buy
12,628
+5,953
+89% +$716K ﹤0.01% 2433
2020
Q4 		$673K Sell
6,675
-7
-0.1% -$612 ﹤0.01% 2690
2020
Q3 		$438K Buy
6,682
+2,748
+70% +$208K ﹤0.01% 2862
2020
Q2 		$269K Buy
+3,934
New +$269K ﹤0.01% 3078
2019
Q1 		– Sell
-102
Closed -$27K – 3455
2018
Q4 		$27K Buy
+102
New +$49.1K ﹤0.01% 3314
2018
Q2 		– Sell
-374
Closed -$195K – 3264
2018
Q1 		$195K Sell
374
-351
-48% -$215K ﹤0.01% 3182
2017
Q4 		$474K Buy
725
+275
+61% +$181K ﹤0.01% 2901
2017
Q3 		$303K Buy
+450
New +$280K ﹤0.01% 2898
2017
Q2 		– Sell
-219
Closed -$126K – 3192
2017
Q1 		$126K Buy
+219
New +$141K ﹤0.01% 3053
2015
Q1 		– Sell
-45
Closed -$44K – 3162
2014
Q4 		$44K Sell
45
-169
-79% -$147K ﹤0.01% 2884
2014
Q3 		$197K Buy
214
+141
+193% +$151K ﹤0.01% 2555
2014
Q2 		$91K Buy
73
+28
+62% +$35K ﹤0.01% 2675
2014
Q1 		$60K Buy
45
+28
+165% +$46K ﹤0.01% 2748
2013
Q4 		$29K Sell
17
-86
-83% -$139K ﹤0.01% 2806
2013
Q3 		$135K Buy
103
+53
+106% +$62.6K ﹤0.01% 2651
2013
Q2 		$48K Buy
+50
New +$51.8K ﹤0.01% 2699

Other funds holding BLRX

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
BCV
Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.21B AUM 33.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Renaissance Technologies's BLRX Position: Q2 2026 in Review

Renaissance Technologies opened a new position in BioLineRX (BLRX) in Q2 2026: 15,412 shares worth $48.1K. The stake represents ﹤0.01% of the portfolio and ranks #3050 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in BLRX as recently as Q2 2023.

Renaissance Technologies first reported a position in BLRX in Q2 2013 and has held it in 26 quarters since. The position peaked at $1.41M in Q1 2021. 14 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

  • Renaissance Technologies held 15,412 shares of BioLineRX worth $48.1K as of Q2 2026.
  • BioLineRX was a new Renaissance Technologies position in Q2 2026.
  • BioLineRX made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #3050 holding.
  • Renaissance Technologies first reported a position in BioLineRX in Q2 2013 and has held it in 26 quarters since.
  • Renaissance Technologies's BioLineRX position peaked at $1.41M in Q1 2021.
  • 14 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.